Kealan Hobelmann

Thomas Jefferson University

Papers

2

Total Citations

43

H-Index

2

About

Kealan Hobelmann is a surgical oncologist whose research focuses on refining treatment strategies for oropharyngeal squamous cell carcinoma (OPSCC), with a particular emphasis on the interplay between patient risk factors and surgical outcomes. His major contributions center on the use of transoral robotic surgery (TORS) as a primary treatment modality, investigating how patient characteristics and post-operative imaging can guide prognosis. In a highly cited 2020 study (38 citations), Hobelmann demonstrated that smoking significantly worsens disease-specific survival in patients with HPV-positive OPSCC treated with TORS, challenging the assumption that favorable viral-status outcomes are uniform across all patients. This work has critical implications for risk stratification and adjuvant therapy decisions. He also explored the predictive value of post-treatment PET/CT imaging after TORS, contributing to evidence-based surveillance protocols. By bridging surgical technique with personalized risk assessment, Hobelmann’s research helps clinicians better identify which patients may benefit from more aggressive adjuvant treatment, ultimately improving survival outcomes in this complex patient population.

Research Focus

Key Achievements

2
H-Index
2
Papers
43
Total Citations
22
Avg Citations/Paper
🏆 Most Cited Paper
Evaluating the impact of smoking on disease‐specific survival outcomes in patients with human papillomavirus–associated oropharyngeal cancer treated with transoral robotic surgery
38 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Thomas Jefferson University

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago